<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03597568</url>
  </required_header>
  <id_info>
    <org_study_id>201806073</org_study_id>
    <nct_id>NCT03597568</nct_id>
  </id_info>
  <brief_title>Resveratrol and Vascular Function in CKD</brief_title>
  <official_title>Effect of 6 Weeks Resveratrol Supplementation on Vascular Function in CKD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diana Jalal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed research is clinical study evaluating the therapeutic benefits of resveratrol on&#xD;
      vascular function in patients with chronic kidney disease (CKD). The study aims to establish&#xD;
      that resveratrol will improve endothelial function and functional performance by reducing&#xD;
      oxidative stress and in conjunction with lowering markers of inflammation and oxidative&#xD;
      stress.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with chronic kidney disease (CKD) have an exceptionally high risk for cardiovascular&#xD;
      disease (CVD), and are 10 times more likely to die from CVD prior to requiring dialysis or&#xD;
      kidney transplantation. Inflammation, oxidative stress and vascular dysfunction (impaired&#xD;
      endothelial function and increased large elastic artery stiffness), are highly prevalent in&#xD;
      CKD and contribute to the high incidence of CVD in this patient population. In addition,&#xD;
      patients with CKD suffer from high rates of cognitive decline for which we lack effective&#xD;
      therapies. Thus, therapeutic interventions targeting inflammation, oxidative stress, vascular&#xD;
      dysfunction in CKD are a priority.&#xD;
&#xD;
      Wine intake, which is known to be rich in various polyphenolic compounds, might have a&#xD;
      variety of health benefits. Among these polyphenols, the stilbene derivative resveratrol&#xD;
      (RSV), a naturally occurring polyphenol found in grapes and red wine, has recently come to&#xD;
      light, as it has been shown to exert potent anti-diabetic, anti-oxidative and&#xD;
      anti-inflammatory actions. Importantly, recent studies have demonstrated that resveratrol is&#xD;
      well-tolerated (37) and may confer similar benefits in individuals at high risk of CVD, such&#xD;
      as improved endothelial function in individuals with metabolic syndrome (i.e. diabetes)&#xD;
&#xD;
      The primary goal of this application is to determine whether 6 wks resveratrol (RSV)&#xD;
      supplementation improves vascular function by reducing oxidative stress in a randomized,&#xD;
      double-blind, cross-over study of 25 patients with diabetic kidney disease. The investigators&#xD;
      hypothesize that: 1) 6 wks RSV will improve vascular function as measured via BA-FMD vs.&#xD;
      placebo and 2) that the improvement in vascular function will be related, at least partially,&#xD;
      to a reduction in oxidative stress.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized to either receive the following intervention: placebo or resveratrol for six weeks and then after a two week washout will be assigned the alternate study drug.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular endothelial function</measure>
    <time_frame>6 weeks</time_frame>
    <description>Brachial artery flow-mediated dilation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional work capacity</measure>
    <time_frame>6 weeks</time_frame>
    <description>6-minute walk test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive resveratrol 400 mg PO per day in divided doses of 200 mg in the morning and 200 mg in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo pill identical in appearance and taste to the supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>Oral supplementation for 6 weeks</description>
    <arm_group_label>Resveratrol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral supplementation for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CKD stage III (estimated GFR: 30-60 mL/MIN/1.73m2)&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
          -  Angiotensin converting enzyme inhibitor or angiotensin II receptor bloocker for &gt; 3&#xD;
             month prior to the study&#xD;
&#xD;
          -  Type II diabetes mellitus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Consuming &gt; 2 glasses/day red wine and/or taking resveratrol or vitamin C supplement&#xD;
             in the past 12 months&#xD;
&#xD;
          -  Life expectancy &lt;1 year&#xD;
&#xD;
          -  BMI &gt;40 kg/m2 1&#xD;
&#xD;
          -  Pregnant, breastfeeding, or unwilling to use adequate birth control&#xD;
&#xD;
          -  Uncontrolled hypertension; blood pressure &gt; 140/90&#xD;
&#xD;
          -  Uncontrolled type II DM; AIC &gt; 8.5&#xD;
&#xD;
          -  Currently taking anticoagulants including: coumadin, dalteparin, enoxaparin, haparin,&#xD;
             and plavix.&#xD;
&#xD;
          -  Severe liver disease&#xD;
&#xD;
          -  Severe systolic heart failure&#xD;
&#xD;
          -  Hospitalization within the last 3 months&#xD;
&#xD;
          -  Active infection or antibiotic therapy&#xD;
&#xD;
          -  Immunosuppressive therapy within the last year&#xD;
&#xD;
          -  Currently partaking in another research study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Jalal</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katharine Geasland, Ph.D.</last_name>
    <phone>319-353-6318</phone>
    <email>katharine-geasland@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diana Jalal, MD</last_name>
    <phone>319-356-4113</phone>
    <email>diana-jalal@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52245</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharine Geasland</last_name>
      <phone>319-353-6318</phone>
      <email>katharine-geasland@uiowa.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Diana Jalal</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Resveratrol</keyword>
  <keyword>Kidney Diseases</keyword>
  <keyword>Renal Insufficiency</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

